Summary
AbbVie Inc. reported total net revenues of $54.3 billion for the fiscal year ended December 31, 2023, a decrease of 6.4% on a reported basis compared to the prior year. This decline was primarily driven by the impact of biosimilar competition for Humira, which accounted for approximately 27% of AbbVie's total net revenues in 2023 and faced significant erosion in the US market following the loss of exclusivity in January 2023. Despite the Humira headwinds, AbbVie demonstrated strong performance in its growth products, particularly Skyrizi and Rinvoq, which saw substantial revenue increases of 50.3% and 57.4%, respectively. The company's oncology, aesthetics, and neuroscience portfolios also showed positive growth. AbbVie is strategically investing in its pipeline, evidenced by its approximately 90 compounds in development, and has recently completed the acquisition of ImmunoGen and announced plans to acquire Cerevel Therapeutics, signaling a continued focus on diversification and expansion into new therapeutic areas. The company also continues to return value to shareholders through dividends and share repurchases, with a quarterly dividend increase announced in October 2023.
Financial Highlights
55 data points| Revenue | $54.32B |
| Cost of Revenue | $20.41B |
| Gross Profit | $33.90B |
| SG&A Expenses | $12.87B |
| Operating Expenses | $41.56B |
| Operating Income | $12.76B |
| Interest Expense | $2.22B |
| Net Income | $4.86B |
| EPS (Basic) | $2.73 |
| EPS (Diluted) | $2.72 |
| Shares Outstanding (Basic) | 1.77B |
| Shares Outstanding (Diluted) | 1.77B |
Key Highlights
- 1AbbVie's total net revenues decreased by 6.4% to $54.3 billion in 2023, primarily due to the loss of Humira exclusivity and subsequent biosimilar competition, which impacted US sales significantly.
- 2Skyrizi and Rinvoq, key growth drivers for AbbVie, experienced robust revenue increases of 50.3% and 57.4% respectively, demonstrating strong market uptake and indication expansion.
- 3The oncology portfolio, including Imbruvica and Venclexta, saw a revenue decline of 21.3% and a growth of 13.9%, respectively, with Imbruvica facing demand and market share challenges.
- 4Aesthetics and Neuroscience segments showed positive growth, with Botox Cosmetic up 2.6% and Vraylar revenue increasing by 35.4%, driven by market growth and new indications.
- 5The company is actively expanding its pipeline and business through strategic acquisitions, notably the completion of the ImmunoGen acquisition and the proposed acquisition of Cerevel Therapeutics.
- 6AbbVie's research and development expenses increased by 18% to $7.7 billion, reflecting continued investment in its pipeline of approximately 90 compounds in development.
- 7The company returned significant capital to shareholders through dividends ($10.5 billion) and share repurchases ($1.6 billion) in 2023, while also managing its debt profile.